{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-052112","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2026-08-04T10:31:28+00:00","discovered_at":"2026-08-04T10:35:00.447678+00:00","generated_at":"2026-08-04T10:35:25.016046+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InfuSystem Q2 net revenue $36.9M, up 2.6%; net income $3.2M; reaffirms 2026 guidance","bullets":["Net revenues $36.9M (+2.6% YoY); Patient Services +15% to $24.8M, Device Solutions -16% to $12.1M.","Net income $3.2M ($0.15 diluted EPS) vs $2.6M ($0.12) prior year; Adjusted EBITDA $8.6M (+7.6%), margin 23.4%.","Reaffirmed FY 2026 guidance: pro-forma revenue growth 6-8%, Adjusted EBITDA margin mid-to-low 20s.","Stock repurchases $3.5M in Q2; liquidity $55.2M as of June 30, 2026.","GE Healthcare contract restructuring cut Device Solutions revenue $1.6M but improved profitability and margins."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-052112","json":"https://secwatch.observer/filing/0001628280-26-052112.json","markdown":"https://secwatch.observer/filing/0001628280-26-052112.md","text":"https://secwatch.observer/filing/0001628280-26-052112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026052112/0001628280-26-052112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026052112/infu-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T10:35:25.016046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}